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Aims:  Although people screened as being hyperglycaemic often fail to follow up with 
physicians for clinical assessment, epidemiologic findings on the frequency and predictors of not 
following up (hereafter, “no follow-up”) are lacking. The purpose of this study was to examine 
the no follow-up rate with physicians after screening for diabetes and its predictors. 
 
Methods:  We assessed cases of no follow-ups with physicians within six months after 
screening based on medical claims data from employee-based social health insurance programs in 
Japan, for people aged 20 to 68 years from 2005 to 2010. 
 
Results:  Among 3,878 screened participants with hyperglycemia, 2,527 (65%) did not follow 
up with their physicians within six month after screening. Multiple logistic regression analysis 
revealed that younger age and lower blood glucose level predicted no follow-ups among both 
men and women, while lower body mass index and negative proteinuria also predicted no 
follow-ups among men. Treatment for dyslipidaemia facilitated follow-ups among both genders, 
and treatment for hypertension or depression facilitated follow-ups among men. 
 
Conclusions:  Approximately two thirds of individuals screened as having hyperglycemia did 
not follow up with their physicians within six months after screening. Predictors of no follow-ups 
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Diabetes mellitus is associated not only with the occurrence of vascular complications, but also 
with impaired quality of life and increased health care costs1-3. In 2013, 382 million people had 
diabetes in the world; this number was expected to rise to 592 million by 20354. The total number 
of excess deaths attributable to diabetes in 2010 was estimated to be 3.96 million in the age group 
of 20-79 years5. Approximately 17% of the Japanese population is estimated to have diabetes, and 
this number increases every year6. 
 
The effectiveness of screening for diabetes remains controversial7-14. In Japan, a unique system of 
general health screening that includes glucose testing was established by the Health and Medical 
Service Act for the Aged in 1983. Screenings have been conducted primarily at worksites or local 
community facilities, and patients who screen positively are advised to follow up with a physician. 
Thus, following up with a physician is a requisite for this screening system to work. A Japanese 
national survey based on self-report revealed that 39% of people with diabetes had not been 
treated6, indicating that many individuals who are potentially diabetic neither visited nor followed 
up with physicians. 
 
A previous cross-sectional study based on self-report suggested that younger people and those 
with lower risk were more likely to drop out from screenings15. Another cross-sectional study 
reported that individuals with type 2 diabetes who suffer from depression poorly adhere to 
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self-care16. Yet, no study has reported longitudinal findings using objective data to address this 
issue. To this end, we conducted a cohort study to examine the characteristics of people who did 
not follow up with physicians for clinical assessment after they were screened as being 
hyperglycaemic, with a focus on age, severity of hyperglycemia and comorbidities. 
 
Materials and Methods 
Setting 
In Japan, all people have been insured under universal health coverage since 1961, which 
primarily consists of employee-based and community-based social health insurance programs17. 
The Industrial Safety and Health Law enacted in 1972 requires that public screening services be 
provided at worksites or local community facilities, rather than taking place at a family or 
attending physician’s office as in the United States and other countries.  
 
In order to obtain a confirmed diagnosis or to initiate treatment after screening, screened 
individuals with a positive test result must follow up with physicians (Figure 1). In Japan, 
standard screening for adults was implemented by the Law of Health and Medical Services for 
the Elderly from 1983 to 2008, although it is now under the control of the Act on Assurance of 
Medical Care for Elderly People, which was enacted in 2008. Our data include both periods. Both 
laws instruct those whose examined values exceed cut-off values to visit physicians, and most 
health insurance programs advise them to do so simply by mail. Disease management, including 
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education, monitoring or feedback, for screened people is not proactively carried out by the 
government Rather, disease management differs by the particular health insurance system. 
Screened people generally receive instructions to consult with a physician within about two 
months of the screening, although a medical institution or timing of the visit is not specified. That 
is, in Japan, although health insurance plans provide screening to insured people, the plans fall 
short of designating a hospital. This reflects the disconnect between health insurance programs 
and hospitals, although regular health check-ups are the norm and mass screening is provided for 
everyone at school and work or in the community18. 
 
In 2007, the Ministry of Health, Labour and Welfare proposed a standard program for screening 
and health guidance19, and screenings are currently conducted according to this program. 
Screenings are held by each health insurance program, although the frequency differs by program. 
Most screenings are held during the day, and blood and/or urine samples are collected early in the 
morning. Screened participants are instructed to fast from 9 p.m. the night before to the end of 
screening, although the degree of compliance with these instructions is unclear. In general, there 
are two approaches to the screening. Either people visit a specifically-designated facility to 
receive the check-up, or screeners visit the worksite. For worksite-based screenings in our study, 
vehicles carrying medical testing equipment visited each worksite and carried out the screenings. 
Depending on the insurance program, some participants visited a facility designated by the 
program to undergo screening. For community-based screenings, non-employed people typically 
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visit local facilities. 
 
Screening services follow several general steps that represent the analytical framework for 
diabetes screening8. We reworked this framework to adapt it for diabetes screening in Japan 
(Figure 1). As mentioned above, Japanese screenings are held mainly at community facilities or 
worksites (Step 1 in Figure 1), followed by visiting physicians (Step 2 in Figure 1). For the 
screening program to work effectively, people need to adhere to all steps.  
 
Study design and data source  
We carried out a retrospective cohort study using administrative data from both health insurance 
claims and screenings from Japan Medical Data Center Co., Ltd. (JMDC, Tokyo, Japan). JMDC 
obtained health insurance claims and screening data from several employee-based social health 
insurance plans and constructed the JMDC medical database (JMDC-MDB). This database 
includes 530,000 insured people and their dependents, mainly company employees and their 
family members, from January 2004 to December 2010. Health insurance claims were 
anonymously linked with screening data in JMDC-MDB20. The database provided patient 
demographics, screening results, test orders, treatments, prescribed drugs and hospital diagnoses. 
The locality of the health insurance plans or the identities of the insured were not available to the 
researchers. Under these circumstances, all employees and family members were automatically 
eligible for the screening and were encouraged to attend it. 
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 The Institutional Review Board of the Kyoto University Graduate School and Faculty of 
Medicine Ethics Committee approved the study protocols (E1017). 
 
Study participants 
Study participants were screened individuals with untreated hyperglycemia. The study cohort 
included 220,409 employees and their dependent family members, from 2005 to 2010. Of the 
220,409 participants, we excluded 118,765 who did not attend a screening (screening attendance 
rate: 46%) and 9,749 who did not undergo glycated haemoglobin (HbA1c) or fasting glucose tests. 
Of the remaining 91,895 participants, 5,834 participants (6.3%) were considered hyperglycaemic 
(HbA1c ≥ 6.5% [48 mmol/mol], or fasting glucose ≥ 126 mg/dl). Of these, 1,927 were being 
treated with antihyperglycaemic agents. When participants were identified as hyperglycaemic 
twice or more, we defined “hyperglycaemic at screening” as the last time of screening in the study 
period. We excluded people who were born before 1940 (n=19) because of missing birth dates, 
and people who were under 20 years at the time of screening (n=10). Data from the remaining 
3,878 participants (3,420 men and 458 women) were analysed (Figure 2). 
 
Outcome measurement 
“Follow-up” refers to the initial visit to a physician within six months after the screening, 
accompanied by an examination of HbA1c and/or glucose. When a participant who screened 
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positive did not follow up with a physician, this was designated as “no follow-up”, which was 
regarded as the primary outcome measurement. We determined the indicated visit as being for 
treatment of diabetes or not according to whether further glycaemia testing, an examination of 
HbA1c and/or glucose was done at the visit. Those who visited a physician for the other diseases 
(e.g., common cold) were excluded. Whether patients were on track for treatment or not is beyond 
the scope of the present study, and thus “follow-up” also included those who made even a single 
visit to a physician. For the most part, screenings are performed once (although in some cases, 
twice a year). Accordingly, the primary outcome measure for this study was “no follow-up with a 
physician within six month after screening.” For sensitivity analysis, we also examined no 
follow-up with a physician within three and 12 months of screening. 
 
Baseline variables 
Demographic characteristics and screening data for participants were obtained directly from 
JMDC-MDB. Body mass index (BMI [kg/m2]) was calculated from weight and height measured 
during screening as a measure for obesity. HbA1c values determined by the Japan Diabetes 
Society (JDS) method was 0.4% lower than NGSP values21, so we converted them to NGSP 
values. 
 
We identified comorbidities using information from health insurance claims on hypertension 
treatment, dyslipidaemia, proteinuria and depression. Hypertension and dyslipidaemia are chronic 
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metabolic diseases that, like hyperglycemia, require drug therapy and lifestyle modification. We 
hypothesized that participants being treated for these diseases may be more likely to follow up 
with physicians if they were hyperglycaemic at screening. Proteinuria was chosen as a marker of 
possible chronic kidney disease. A previous study reported that depression is associated with 
non-adherence to diabetes self-care among patients with type 2 diabetes16, implying that 
depression precludes engaging in desirable health behaviours. Therefore, treatment for depression 
was included as a potential predictor of non-adherence to follow-ups. We defined “hypertension” 
as prescription of hypertension medication within three months prior to screening: C02, 03, 04, 07, 
08, or 09 in the Anatomical Therapeutic Chemical Classification System22. Similarly, we defined 
“dyslipidaemia” as prescription of medication for dyslipidaemia (C10), and “depression” as 
prescription of medication for depression (N06A or N06BA). Participants who were diagnosed 
with hypertension, dyslipidaemia and/or depression were excluded if their comorbidities were left 
untreated. “Glycosuria” was classified as either negative (urine dipstick, negative) or positive 
(urine dipstick, trace or above). Proteinuria was also classified as negative (urine dipstick, 
negative or trace) or positive (urine dipstick, 1+ or above). For patients who already had 
hypertension or dyslipidaemia, we examined whether they visited the same clinics for 
hyperglycemia as for these other diseases. Men and women were analysed separately. 
 
Smoking (yes/no) and frequency of alcohol consumption (everyday/sometimes/rarely) were 
self-reported and missing in a considerable proportion of the participants (23% and 36%, 
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respectively); participants without these data were excluded from the analysis. Given the lack of 
data regarding education level, marital status, race or ethnicity, type of employee-based social 
health insurance plan and insured/dependent individual were used as surrogates of these 
socio-economic variables. 
 
Statistical analysis  
We identified mean or median values, and frequencies of explanatory variables that were potential 
predictors or confounders, stratified by gender. We excluded variables if there were more than 
20% missing data. For the remaining variables, we used mean values for missing data of 
continuous variables, and “no” for dichotomous variables. 
 
We calculated the frequency of no follow-ups after screening, and used logistic regression models 
to estimate odds ratios (ORs) and 95% confidence intervals (CIs) to determine predictors. As 
explanatory variables, we used baseline variables for which there were less than 20% missing 
data (age, gender, HbA1c, fasting glucose, BMI, glycosuria, proteinuria, haemoglobin, 
hypertension, dyslipidaemia, depression, type of health insurance plans and insured/dependent 
status at the health insurance plans). Multiple logistic regression analyses were performed 
following analyses using age-adjusted models. We also analysed data for two additional 
follow-up periods: within three months and within 12 months. The statistical models were 
examined using the area under the receiver operating characteristic (ROC) curve (C statistic). 
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Tests of statistical significance were two-tailed, with an α-level of 0.05. All analyses were 
performed with STATA, version 11.1 (Stata Corp., College Station, TX, USA). 
 
Results 
Screening attendance rate and baseline characteristics of participants with hyperglycemia 
Among 101,644 of 220,409 cohort members who participated in a screening (attendance rate: 
46%), 91,895 underwent glucose testing, of whom 5,834 (6.3%) were hyperglycaemic and 3,907 
(4.3%) were hyperglycaemic without treatment. There were 3,878 study participants remaining 
after excluding those under 20 years of age or born in 1940 or before (Figure 2). HbA1c and 
fasting glucose levels were used to identify participants with suspected diabetes (i.e., if they had 
values higher than the cut-off). Among the 3,878 study participants, HbA1c and fasting glucose 
were examined in 3,784 (97.6%) and 3,363 (86.7%) participants, respectively. For 94 (2.4%) 
participants, only data for fasting glucose were available. 
 
We used age, gender, HbA1c, fasting glucose, BMI, glycosuria, proteinuria, haemoglobin, 
hypertension, dyslipidaemia, depression, type of health insurance plan, and insured/dependent 
status in the health insurance plan as variables; these data were complete or missing less than 20% 
(Table 1). 
 
Table 1 shows the baseline characteristics of 3,878 participants screened as hyperglycaemic. More 
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men than women had higher haemoglobin levels (15.2 g/dl vs. 13.1 g/dl), were more likely to 
smoke (40.4% vs. 7.6%), consumed alcohol more frequently (14.4% vs. 2.0% for everyday 
drinking), had depression more often (2.3% vs. 6.6% for depression), had hypertension more 
often (16.9% vs. 13.8%) and were insured (99.97% vs. 49.1%). 
 
Frequency of no follow-up 
Of the 3,878 hyperglycaemic participants, 2,527 (65.2%) did not follow up with physicians within 
six months (Figure 2, Table 1). Men were less likely to follow up with physicians than women 
during the three, six, and 12-month follow-up periods (74.9% vs. 67.0%, 65.9% vs. 59.4% and 
58.2% vs. 53.7% for no follow-ups, respectively). When stratified by HbA1c levels, >40% of 
participants with an HbA1c of 8.0% (64 mmol/mol) or over, and 35% of participants with HbA1c 
of 10.0% (86 mmol/mol) or over, did not follow up with physicians within six months (Table 2). 
 
Frequency of follow-up with physicians treating pre-existing conditions 
For participants being treated for hypertension (n=640) or dyslipidaemia (n=410), 367 (57%) of 
those with hypertension and 270 (66%) of those with dyslipidaemia followed up with physicians 
after screening for diabetes. Most of these participants followed up with the physicians who were 
already treating them (80%: hypertension, 90%: dyslipidaemia). 
 
Predictors of no follow-up 
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Table 3 shows age-adjusted analyses for predicting no follow-ups. Lower BMI, lower glucose 
level and negative proteinuria predicted no follow-ups in men, while treatment for comorbidities 
(hypertension, dyslipidaemia and depression) facilitated follow-ups. Lower glucose level, 
negative proteinuria and insured status predicted no follow-ups in women, while treatment for 
comorbidities (hypertension and dyslipidaemia) facilitated follow-ups. 
 
Table 4 shows the adjusted ORs and 95% CIs for no follow-ups by each variable. This multiple 
logistic regression analysis revealed that younger age, lower BMI, lower glucose level and 
negative proteinuria significantly predicted no follow-ups in men, while treatment for 
comorbidities (hypertension, dyslipidaemia and depression) facilitated follow-ups. For women, 
younger age and lower glucose level predicted no follow-ups, while treatment for comorbidities 
(dyslipidaemia) facilitated follow-ups. Areas under the ROC curve for the multiple logistic 
regression models were 0.72, 0.73 and 0.74 for men and 0.74, 0.76 and 0.77 for women at three, 
six and 12 months, respectively. 
 
Discussion 
We showed that 2,527 of 3,878 individuals (65.2%; 65.9% of men and 59.4% of women) who 
were hyperglycaemic without treatment at the time of screening did not follow up with physicians 
within six months after the screening. Younger age, lower blood glucose level, lower BMI and 
negative proteinuria predicted no follow-ups, while treatment for comorbidities (hypertension, 
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dyslipidaemia or depression) facilitated follow-ups. Our study is the first to reveal the frequency 
and predictors of no follow-ups in the Japanese diabetes screening system using a large database 
that links health claim data with mass screening results. 
 
Direct evidence of the effectiveness of diabetes screening and its clinical implementation is 
lacking (Key Question 1 in Figure 1), although there have been several previous studies 
addressing this7-14, 23, 24. The U.S. Preventive Services Task Force summarizes screening for type 2 
diabetes mellitus in adults as a grade I statement, meaning that current evidence is insufficient to 
assess the service7. A modelling study simulated that screening for type 2 diabetes would be 
cost-effective when initiated between the ages of 30 and 45 years, and repeated every three to five 
years25. Another study suggested that screening for type 2 diabetes and early intensive 
multifactorial treatment were feasible in general practice13. Adverse outcomes from diabetes 
screenings were not apparent in previous studies26-29, possibly because the studies did not 
sufficiently analyse dropout cases. Focus should also be placed on these cases in order to increase 
the effectiveness of diabetes screenings. 
 
The screening attendance rate in the present study was 46% (Figure 2), and was 78% among 
insured participants and 29% among dependents, which was similar to results of a Japanese 
national survey that showed 62% of citizens attended a general health screening (employed: 69%, 
unemployed: 49%)30. The screenings involved measurements of HbA1c and fasting or casual 
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blood glucose to identify individuals who are possibly diabetic. Participants were instructed to 
fast beginning at the night before the screening, and for those who failed to maintain the fasting 
requirement, casual blood glucose was measured and the time since the last meal was recorded. In 
the present study, only HbA1c and fasting glucose were used to identify participants because 
these measurements are more stable than that of casual blood glucose. Participants were 
considered to be potentially diabetic if they had values above the cut-off for HbA1c and/or fasting 
glucose.  
 
The rate of no follow-ups after screening was much higher in the present study (step 2 in Figure 
1) than in national data showing that 39% of people with diabetes were not being treated6. This 
discrepancy can be attributed to the difference in research design. The national survey6 was based 
on self-report and could be affected by information bias, whereas our study used objective 
administrative data from health insurance claims and screenings. Moreover, the sampling process 
differed in that participants of the national survey were those who answered ‘I have never been 
treated’ or ‘I was treated in the past, but not currently’ to the question ‘have you ever been referred 
to as a diabetic at a screening or at a medical institution?’ In contrast, we asked the question “how 
many individuals did not follow up after screening positive for potential diabetes.” Another 
previous study reported a 50% response rate to a pre-screening questionnaire for diabetes, and 
77% of respondents at high risk for diabetes visited clinics15. Although the follow-up rate after 
screening was higher in the previous study than in ours, it was conducted in an interventional 
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study setting and did not represent actual behaviour after screenings. Also, while it has been 
suggested that screening programs should follow-up on positive tests31, specific goals have not 
been set. It may be worth examining a concrete follow-up process to screening in the future. Even 
with moderate to severe hyperglycaemia, considerable proportions of participants did not follow 
up with physicians (Table 2). Surprisingly, one third of participants with an HbA1c value of 10% 
(86 mmol/mol) or over failed to follow up with physicians. This highlights the urgent need for 
screeners to develop an effective reminder/recall system for such individuals. In addition, 
potential barriers to following up, e.g., pressure against leave work to visit doctors, need to be 
further investigated. 
 
Our study identified a number of predictors for no follow-ups. The first was younger age. 
Younger people may lack awareness regarding the risks of hyperglycaemia and are less 
health-conscious than older people. Most of the younger people were working, and would not go 
to clinics if they were experiencing no symptoms or only mild symptoms because of their 
environment. This finding was consistent with that of the previous study15. 
 
Second, lower BMI predicted no follow-ups in men. Some studies reported that obese people tend 
to visit general practice physicians more often than non-obese people32, 33. Although our study 
was conducted in a screening setting, our results support the generalization that obese men are 
more likely to follow up with physicians than non-obese men. There are two possible reasons for 
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this: (1) obesity increases the risk of diseases that require treatment, and (2) obesity increases a 
patient’s sense of risk and leads to follow-up with physicians. On the other hand, obese women 
tended not to follow up with physicians. This implies that obese women might be less health 
conscious than obese men, and the tendency of obese individuals to engage in healthy behaviours, 
including follow-ups with physicians, might be influenced by gender. Examination of this 
hypothesis is beyond the scope of our study and further study will be needed to address this issue. 
 
Third, lower blood glucose level predicted no follow-ups. This is related to a lack of risk 
awareness, similar to that found for age differences. Also, the above-mentioned study suggested 
that dropouts at the screening step were more likely to have lower risk scores on the pre-screening 
questionnaire15. 
 
Fourth, having or being treated for comorbidities including hypertension, dyslipidaemia, 
proteinuria and depression tended to facilitate follow-ups. Furthermore, over 80% of people who 
had been treated for hypertension or dyslipidaemia visited the same physicians after screening as 
hyperglycaemic. Treatment for comorbidities, particularly hypertension and dyslipidaemia, 
increased the likelihood that people who were hyperglycaemic at screening would follow up with 
physicians and receive clinical care. This suggests that many patients tend to attend the same 
clinics as part of the free access system in Japan. A previous study reported that patients with type 
2 diabetes who are depressed poorly adhere to self-care16; however, the definition of depression in 
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this report was based only on self-reported data, which is different from the definition adopted in 
our study. Our study participants who were classified as depressed were undergoing treatment and 
might have been more inclined to comply with instructions after screening. A lack of risk 
awareness, as discussed above, may be associated with proteinuria as well. 
 
Sensitivity analyses was also conducted to examine differences in follow-up periods. When 
setting three or 12 months as the follow-up period, all explanatory variables showed similar trends 
as those for the six-month follow-up. Moreover, multiple logistic regression models and ROC 
curves were used to assess the ability of these models to predict outcomes. AUCs showed 
acceptable discrimination, with values ranging from 0.72 to 0.77. 
 
There are some limitations to this study. First, smoking and alcohol consumption were not 
included in the analysis due to missing data. Consequently, this study may not have considered 
potentially important information on behavioural factors. Second, as information on 
socioeconomic status was not available, we used the type of health insurance plan and 
insured/dependent status as surrogates for socioeconomic status. In Japan, the particular company 
one works for dictates the health insurance plan one has. While the type of health insurance plan 
and insured/dependent status have limitations as surrogates of socioeconomic status, the focus of 
the present study was the middle-aged working class of company employees, rather than a 
representative population comprising socially diverse sub-populations from around Japan. Given 
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this design, our study population could be considered more socially homogeneous than a national 
representative population. The existence of unadjusted variables (i.e., residual confounding) may 
have limited the fitness of the obtained models. Third, the analysed data were only from three 
employee-based health insurance plans. As a result, the participants were younger than the 
general Japanese population and the number of women was limited. Therefore, extrapolation of 
the present findings to other Japanese populations, especially elderly people requires careful 
consideration. On the other hand, recent clinical guidelines34 have reconsidered the strict 
glycaemic goals for treating older adults with diabetes, and aggressive screening for older adults 
to detect possible diabetes remains controversial35, 36. Against this backdrop, our focus on a 
younger population (working-age adults) would contribute to maintaining work productivity in 
society. 
 
In conclusion, we found that two-thirds of participants who were hyperglycaemic did not follow 
up with physicians after screening. Younger age, lower BMI, lower blood glucose level and 
negative proteinuria predicted no follow-ups, and treatment for comorbidities including 
hypertension, dyslipidaemia and depression facilitated follow-ups. To improve the screening 
system and health care cost efficiency, a more effective follow-up process that includes 
recommendations to visit physicians must be offered to those at high risk of not following up. 
Further studies will be needed to accurately evaluate diabetes screening, including no attendance 
or no follow-ups, which will contribute to a more effective health care system. 
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Fig. 1 - Japanese diabetes screening process. 
Note: Screenings are primarily taken place at work sites or local community facilities, and 
screened patients are advised to follow up with physicians after screening. 
KQ, key question(s); 
KQ1: Is there direct evidence that systematic screening for diabetes among asymptomatic adults 
improves health outcomes?  
KQ2: Does follow-up with physicians early after screening for diabetes provide an incremental 
benefit in health outcomes?  
KQ3: Does initiating early treatment for type 2 diabetes as a result of screening provide an 
incremental benefit in health outcomes ?  
Does initiating early treatment of impaired fasting glucose or impaired glucose tolerance as a 
result of screening provide an incremental benefit in final health outcomes?  
Step 1: Attending diabetes screening 
Step 2: Follow-up with physicians after screening 
Step 3: Initiation of appropriate treatment 
 
 
Fig.2 - Flowchart of the study participants. 




Table 1 - Characteristics of 3878 participants with hyperglycemia, stratified by gender 
 Men (n=3420) Women (n=458) 
No follow-ups with physicians, n (%)   
  0-3 months 2563 (74.9) 307 (67.0) 
  0-6 months 2255 (65.9) 272 (59.4) 
  0-12 months 1989 (58.2) 246 (53.7) 
Mean age (SD), years                              47 (10) 47 (11) 
Age groups, n (%)   
  20-24 years 43 (1.3) 7 (1.5) 
  25-29 years 53 (1.6) 12 (2.6) 
  30-34 years 334 (9.8) 45 (9.8) 
  35-39 years 429 (12.5) 63 (13.8) 
  40-44 years 542 (15.9) 73 (15.9) 
  45-49 years 539 (15.8) 41 (9.0) 
  50-54 years 433 (12.7) 65 (14.2) 
  55-59 years 607 (17.8) 83 (18.1) 
  60-64 years 414 (12.1) 60 (13.1) 
  65-68 years 26 (0.76) 9 (2.0) 
Mean body mass index (SD), kg/m
2a  25.1 (4.4) 25.0 (5.4) 
Mean fasting glucose (SD), mg/dlb 141.0 (34.5) 135.7 (38.0) 
Mean HbA1c (SD), %c 6.5 (1.3) 6.6 (1.4) 
Glycosuria, n (%)d 758 (22.2) 63 (13.8) 
Proteinuria, n (%)d 223 (6.5) 26 (5.7) 
Hypertension, n (%) 577 (16.9) 63 (13.8) 
Dyslipidemia, n (%) 357 (10.4) 53 (11.6) 
Depression, n (%) 8 (0.2) 3 (0.7) 
Smoking, n (%)e 1383 (40.4) 35 (7.6) 
Alcohol consumption, n (%)f   
Everyday 493 (14.4) 9 (2.0) 
Sometimes 772 (22.6) 38 (8.3) 
Rarely 897 (26.2) 262 (57.2) 
Missing data 1258 (36.8) 149 (32.5) 
Mean haemoglobin (SD), g/dlg 15.2 (1.2) 13.3 (1.6) 
Health insurance plans, n (%)   
A 612 (17.9) 104 (22.7) 
B 2702 (79.0) 343 (74.9) 
C 106 (3.1) 11 (2.4) 
Insured status at the health insurance plans, n (%) 3419 (99.97) 225 (49.1) 
 
aData missing for 1 man. 
bData missing for 497 men and 18 women. 
cData missing for 89 men and 6 women. 
dData missing for 149 men and 7 women. 
eData missing for 787 men and 113 women. 
fData missing for 1258 men and 149 women. 













Table 2 - No follow-ups with physicians after screening, stratified by HbA1c 
HbA1c 
No follow-ups with physicians 
3 months 6 months 12 months 
total, N (%) men, N (%) women, N (%) total, N (%) men, N (%) women, N (%) total, N (%) men, N (%) women, N (%) 
< 6% 1471(84) 1332(85) 139(78) 1394 (80) 1255 (80) 139 (78) 1296(74) 1165(74) 131(73) 
6% ≤, < 7% 1063(69) 935(70) 128(62) 875 (57) 771 (58) 104 (50) 735(47) 646(48) 89(43) 
7% ≤, < 8% 165(57) 146(58) 19(53) 126 (44) 110 (43) 16 (44) 97(34) 83(33) 14(39) 
8% ≤, <10% 120(61) 111(62) 9(56) 96 (49) 89 (49) 7(44) 80(41) 74(41) 6(38) 
10% ≤ 46(46) 39(51) 7(37) 35 (35) 29 (36) 6 (32) 27(27) 21(26) 6(32) 
 
Table 3 - Age-adjusted Odds Ratios for No Follow-ups, Stratified by Gender 
  Men Women 
 
3 months 6 months 12months 3 months 6 months 12months 
  OR (95% CI)a OR (95% CI)a OR (95% CI)a OR (95% CI)a OR (95% CI)a OR (95% CI)a 
Body mass index, 1 kg/m2 increase 0.95(0.93-0.96) 0.93 (0.91-0.94) 0.92(0.91-0.94) 0.98(0.94-1.02) 0.97 (0.93-1.00) 0.96(0.92-0.99) 
Fasting glucose, 10 mg/dl increase 0.93(0.91-0.95) 0.95 (0.93-0.97) 0.95(0.93-0.97) 0.97(0.92-1.02) 0.97 (0.92-1.02) 0.99(0.94-1.04) 
HbA1c, 1% increase 0.69(0.65-0.73) 0.65 (0.61-0.69) 0.61(0.57-0.65) 0.74(0.64-0.87) 0.68 (0.58-0.81) 0.70(0.59-0.84) 
Glycosuria 0.59(0.49-0.70) 0.59 (0.50-0.69) 0.55(0.46-0.64) 0.29(0.17-0.52) 0.25 (0.14-0.46) 0.28(0.15-0.51) 
Proteinuria 0.54(0.41-0.72) 0.50 (0.38-0.66) 0.46(0.35-0.61) 0.32(0.14-0.73) 0.39 (0.17-0.92) 0.42(0.18-1.02) 
Hypertension 0.43(0.35-0.52) 0.39 (0.32-0.47) 0.35(0.29-0.43) 0.55(0.31-0.96) 0.44 (0.24-0.79) 0.19(0.09-0.39) 
Dyslipidemia 0.28(0.22-0.35) 0.28 (0.22-0.35) 0.25(0.19-0.32) 0.39(0.21-0.72) 0.28 (0.14-0.56) 0.23(0.93-0.97) 
Depression 0.50(0.37-0.67) 0.18 (0.04-0.90) 0.43(0.32-0.58) 0.81(0.38-1.71) 0.29 (0.02-3.47) 0.58(0.27-1.24) 
Smoking 1.02(0.87-1.20) 0.93 (0.80-1.07) 0.93(0.81-1.07) 0.79(0.37-1.68) 1.11 (0.52-2.37) 1.09(0.52-2.28) 
Alcohol consumption 
      
  Everyday 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
  Sometimes 0.80(0.62-1.03) 0.87 (0.69-1.10) 0.79(0.63-0.10) 2.60(0.58-11.58) 2.91 (0.62-13.7) 2.06(0.44-9.66) 
  Rarely 0.86(0.67-1.12) 0.91 (0.72-1.14) 0.83(0.67-1.05) 2.01(0.52-7.73) 2.25 (0.55-9.29) 1.84(0.45-7.63) 
Haemoglobin (g/dl) 1.02(0.95-1.08) 0.98 (0.92-1.04) 0.96(0.90-1.01) 0.98(0.86-1.11) 0.93 (0.82-1.06) 0.96(0.85-1.09) 
Health insurance plan 
      
A 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
B 1.12(0 .91-1.36) 1.21 (1.01-1.46) 1.25(1.04-1.50) 0.80(0.49-1.31) 0.94 (0.59-1.50) 1.15(0.73-1.84) 
C 0.54(0.35-0.84) 0.82 (0.54-1.25) 0.74(0.48-1.12) 1.04(0.26-4.25) 0.71 (0.20-2.55)  1.08(0.30-3.87) 
Dependent status at health insurance plans NA NA NA 0.57(0.36-0.90) 0.60 (0.39-0.92) 0.49(0.32-0.75) 
NA, Not applicable. 













Table 4 - Adjusted Odds Ratios for No Follow-ups, Stratified by Gender 
  Men Women 
 
3 months 6 months 12months 3 months 6months 12 months 
  OR (95% CI)a OR (95% CI)a OR (95% CI)a OR (95% CI)b OR (95% CI)b OR (95% CI)b 
Age, 10 year increase 0.82(0.75-0.90) 0.78 (0.71-0.85) 0.76(0.70-0.83) 0.82(0.64-1.03) 0.72 (0.57-0.91) 0.76(0.61-0.95) 
Body mass index, 1 kg/m2 increase 0.999(0.98-1.02) 0.979 (0.960-0.998) 0.98(0.96-0.99) 1.02(0.97-1.06) 1.006 (0.965-1.049) 1.001(0.96-1.043) 
HbA1c, 1 % increase 0.69(0.65-0.74) 0.67 (0.62-0.71) 0.64(0.59-0.69) 0.78(0.65-0.92) 0.71 (0.59-0.85) 0.74(0.61-0.89) 
Proteinuria 0.73(0.54-0.99) 0.72 (0.54-0.97) 0.69(0.51-0.94) 0.369(0.15-0.91) 0.53 (0.21-1.34) 0.62(0.24-1.64) 
Hypertension 0.55(0.44-0.68) 0.49 (0.40-0.61) 0.45(0.37-0.56) 0.67(0.36-1.28) 0.57 (0.30-1.09) 0.24(0.11-0.52) 
Dyslipidemia 0.36(0.28-0.46) 0.38 (0.30-0.49) 0.35(0.27-0.46) 0.39(0.20-0.76) 0.31 (0.15-0.63) 0.30(0.13-0.69) 
Depression 0.17(0.04-0.78) 0.14 (0.03-0.74) 0.20(0.04-1.07) 0.19(0.016-2.31) 0.37 (0.03-4.85) 0.41(0.03-5.22) 
Health insurance plan 
      
A 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
B 0.85(0.69-1.06) 0.89 (0.73- 1.09) 0.89(0.73-1.09) 0.58(0.33-1.001) 0.69 (0.40-1.18) 0.76(0.44-1.31) 
C 0.50(0.32-0.78) 0.77 (0.49-1.20) 0.69(0.44-1.07) 0.71(0.15-3.34) 0.54 (0.13-2.21) 0.69(0.17-2.87) 
Dependent status at health insurance plans NA NA NA 0.63(0.36-1.11) 0.74 (0.43-1.27) 0.61(0.35-1.05) 
NA, Not applicable. 
aAdjusted for age, proteinuria, HbA1c, BMI, hypertension, dyslipidemia, depression, health insurance plan. 
bAdjusted for age, proteinuria, HbA1c, BMI, hypertension, dyslipidemia, depression, health insurance plan, and dependent status at the health 
insurance plan. 
